- Source: Dopamantine
Dopamantine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SCH-15507; also known as N-adamantanoyl dopamine) is an antiparkinsonian drug of the adamantane group that developed for treatment of Parkinson's disease but was never marketed. It was developed and studied in the 1970s and was said to have reached early clinical trials.
Dopamantine combines elements of the chemical structures of clinically used adamantane antiparkinsonian agents like amantadine and dopamine or levodopa (L-DOPA) into a single molecule. It is said to have been designed to help dopamine cross the blood–brain barrier via the lipophilic adamantane moiety. The drug is said to share pharmacological effects with amantadine. Another related compound is carmantadine, which is also an adamantane antiparkinsonian agent that was never marketed.
